A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin®) on a named patient basis in Sweden

Acta Oncologica

Volumn 41, Issue 3, 2002, Pages 276-281

  Andersson, J ^b   Linderholm, B ^b   Greim, G ^b   Lindh, B ^b   Lindman, H ^b   Tennvall, J ^b   Tennvall Nittby, L ^b   Pettersson Skold D ^b   Sverrisdottir, A ^b   Soderberg M ^b   Klaar, S ^b   Bergh, J ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; TUMORS;

CLINICAL TRIALS;

PATIENT TREATMENT;

ANTIBODY; ANTINEOPLASTIC AGENT; CARBOPLATIN; CLEMASTINE; DOCETAXEL; MILTEFOSINE; NAVELBINE; PACLITAXEL; PARACETAMOL; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; DYSPNEA; FEVER; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; INFECTION; MEDICAL RECORD; METASTASIS; NAUSEA; NOMENCLATURE; ONCOGENE C ERB; PAIN; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RASH; SWEDEN; TREATMENT FAILURE; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 18444364495     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860260088827     Document Type: Article

References (32)

1. p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity
2. Growth factor receptor tyrosine kinases
3. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
4. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
5. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
6. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
7. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas
8. Oral cancer progression and c-erbB-2/neu proto-oncogene expression
9. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
10. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer
11. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
12. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
13. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
14. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
15. erbB-2 and response to doxorubicin in patients with axillary lymph node- positive, hormone receptor-negative breast cancer
16. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
17. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
18. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
19. Basic science of HER-2/neu: A review
20. Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
21. A systematic overview of chemotherapy effects in breast cancer
22. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2 + /MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
23. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
24. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER +) breast cancer patients with poor prognosis
25. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report
26. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
27. Trastuzumab and chemotherapeutics: Drug interactions and synergies
28. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
29. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
30. Monoclonal antibody therapy in lymphoid malignancies
31. Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside
32. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy